The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.127.2.208

In a double-blind controlled study of 122 patients from four populations, amitriptyline produced the most and placebo the least amount of symptomatic improvement, with trimipramine slightly less efficacious than amitriptyline; general practice patients tended to improve the most and medical clinic patients the least. The authors suggest that amitriptyline may be more potent than trimipramine at equal dosages, as evidenced by its greater production of side effects, and that the small difference in clinical efficacy between the two drugs may thus be dosage related.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.